Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected

Wave Life Sciences Ltd.

WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.
WVE-007 safe/well-tolerated; DMC cleared dose expansion to 600mg and beyond. Body composition/weight data updates expected starting 4Q2025.
WVE-008 selected as PNPLA3-I148M RNA editing candidate for liver disease; CTA filing expected in 2026. Estimated 9M homozygous patients in US/EU.
WVE-006 AATD cohort 3 (600mg) now underway; previously restored 13 µM total AAT with 64% M-AAT. Multidose data expected 1Q2026.
Platform data: single oligonucleotide can simultaneously edit and silence two targets (LDLR up, PCSK9 down) in preclinical models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.